A radioligand binding assay for antitubulin activity in tumor cells

Journal of Biomolecular Screening

Volumn 11, Issue 1, 2006, Pages 82-89

  Young, David H ^a,b   Rubio, Fernando M ^a,c   Danis, Paul O ^a,d  

^a ROHM AND HAAS COMPANY   (United States)

^b DOW AGROSCIENCES LLC   (United States)

^c Eastwoods Consulting   (United States)

^d Applied Biosystems Framingham   (United States)

Author keywords

Benzamide; Cell based binding assay; RH 5854; Tubulin; Tumor cells

Indexed keywords

3 (1 ANILINOETHYLIDENE) 5 BENZYL 2,4 PYRROLIDINEDIONE; ANSAMITOCIN P 3; BENZAMIDE DERIVATIVE; COLCHICINE; NOCODAZOLE; PACLITAXEL; PHOMOPSIN A; PODOPHYLLOTOXIN; PYRROLIDINE DERIVATIVE; RADIOLIGAND; RH 5854; TUBULIN; TUBULOZOLE C; TUBULOZOLE T; UNCLASSIFIED DRUG; VINBLASTINE;

ARTICLE; BINDING SITE; CANCER CELL; CELL ASSAY; COLON CANCER; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG SPECIFICITY; HUMAN; HUMAN CELL; ISOTOPE LABELING; PRIORITY JOURNAL; RADIOASSAY;

BENZAMIDES; BINDING, COMPETITIVE; CELL DEATH; CELL LINE, TUMOR; DRUG INTERACTIONS; DRUG RESISTANCE, MULTIPLE; HUMANS; MICROTUBULES; MITOTIC INDEX; NEOPLASMS; PACLITAXEL; RADIOLIGAND ASSAY; TUBULIN; TUBULIN MODULATORS; VINBLASTINE;

EID: 32844467223     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057105282300     Document Type: Article

References (26)

1. Wilson L, Jordan MA: Pharmacological probes of microtubule function. In Hyams JS, Lloyd CW (eds): Microtubules. New York: Wiley-Liss, 1994: 59-83.
2. Hamel E: Natural products which interact with tubulin in the vinca domain: maytansine, rhizoxin, phomopsin A, dolastatins 10 and 15 and halichondrin B. Pharmac Ther 1992 ; 55: 31-51.
3. Li Q, Sham HL, Rosenberg SH: Antimitotic agents. Ann Rep Med Chem 1999 ; 34: 139-148.
4. Rowinsky EK, Donehower RC: The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics. Pharmac Ther 1991 ; 52: 35-84.
5. Morejohn LC, Fosket DE: Tubulin from plants, fungi, and protists. In Shay JW (ed): Cell and Molecular Biology of the Cytoskeleton. New York: Plenum, 1986: 257-329.
6. Egan AR, Michelotti EL, Young DH, Wilson WJ, Mattioda H: RH-7281: a novel fungicide for control of downy mildew and late blight. Brighton Crop Protection Conference-Pests and Diseases 1998 ; 335-342.
7. Young DH, Lewandowski VT: Covalent binding of the benzamide RH-4032 to tubulin in suspension-cultured tobacco cells and its application in a cellbased competitive-binding assay. Plant Physiol 2000 ; 124: 115-124.
8. Young DH, Slawecki RA: Mode of action of zoxamide (RH-7281), a new Oomycete fungicide. Pestic Biochem Physiol 2001 ; 69: 100-111.
9. Burkhart CA, Kavallaris M, Horwitz SB: The role of β-tubulin isotypes in resistance to antimitotic drugs. Biochim Biophys Acta 2001 ; 1471: O1 - O9.
10. Casazza AM, Fairchild CR: Paclitaxel (Taxol): mechanisms of resistance. Cancer Treat Res 1996 ; 87: 149-171.
11. Monzo M, Rosell R, Sanchez JJ, Lee JS, O'Brate A, Gonzalez-Larriba JL,, et al. Paclitaxel resistance in non-small-cell lung cancer associated with betatubulin gene mutations. J Clin Oncol 1999 ; 17: 1786-1793.
12. Beck WT, Mueller TJ, Tanzer LR: Altered surface membrane glycoproteins in Vinca alkaloid-resistant human leukemic lymphoblasts. Cancer Res 1979 ; 39: 2070-2076.
13. Young DH, Reitz EM: Effects of zarilamide on the in vitro assembly of microtubules and on mitosis in mammalian cells. Schriftenreihe der Deutschen Phytomedizinischen Gesellschaft 1993 ; 4: 381-385.
14. Tiwari SC, Suprenant KA: ApH and temperature-dependent cyclingmethod that doubles the yield of microtubule protein. Anal Biochem 1993 ; 215: 96-103.
15. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970 ; 227: 680-685.
16. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D,, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990 ; 82: 1107-1112.
17. Downing K, Nogales E: Crystallographic structure of tubulin: implications for dynamics and drug binding. Cell Struct Function 1999 ; 24: 269-275.
18. Arai T: Inhibition of microtubule assembly in vitro by TN-16, a synthetic antitumor drug. FEBS Lett 1983 ; 155: 273-276.
19. Russell GJ, Lacey E: Inhibition of [3H]mebendazole binding to tubulin by structurally diverse microtubule inhibitors which interact at the colchicine binding site. Biochem Mol Biol Int 1995 ; 35: 1153-1159.
20. Margolis RL, Wilson L: Addition of colchicine-tubulin complex to microtubule ends: the mechanismof substoichiometric colchicine poisoning. Proc Natl Acad Sci USA 1977 ; 74: 3466-3470.
21. Bai RL, Duanmu C, Hamel E: Mechanism of action of the antimitotic drug 2,4-dichlorobenzylthiocyanate: alkylation of sulfhydryl group(s) of ßtubulin. Biochim Biophys Acta 1989 ; 994: 12-20.
22. Shan B, Medina JC, Santha E, Frankmoelle WP, Chou TC, Learned RM,, et al. Selective, covalent modification of β-tubulin residue Cys-239 by T138067, an antitumor agent with in vivo efficacy against multidrug-resistant tumors. Proc Natl Acad Sci USA 1999 ; 96: 5686-5691.
23. Abraham I, Dion RL, Chi DM, Gottesman MM, Hamel E: 2,4-Dichlorobenzyl thiocyanate, an antimitotic agent that alters microtubulemorphology. Proc Natl Acad Sci USA 1986 ; 83: 6839-6843.
24. Luduena RF, Roach MC: Tubulin sulfhydryl groups as probes and targets for antimitotic and antimicrotubule agents. Pharmac Ther 1991 ; 49: 133-152.
25. Jordan MA, Thrower D, Wilson L: Mechanism of inhibition of cell proliferation by Vinca alkaloids. Cancer Res 1991 ; 51: 2212-2222.
26. Derry WB, Wilson L, Jordan MA: Substoichiometric binding of taxol suppresses microtubule dynamics. Biochemistry 1995 ; 34: 2203-2211.